My top three takeaways from the 2020 San Antonio Breast Cancer Symposium.
This year we’ve seen some encouraging news with approvals of a targeted therapy and an immunotherapy for triple negative breast cancer.
Top “take-home” highlights from the 2019 San Antonio Breast Cancer Symposium.
There were some noteworthy developments this year in targeted therapies for hormone receptor-positive breast cancer.
Findings from the TAILORx clinical trial will help personalize treatment decisions for many patients with early stage breast cancer.
Researchers are working on ways to make immune system therapies more effective for more cancer patients.
Cancer research stories worth following this winter included reports on new approaches to immunotherapy currently being tested in clinical trials.
Recent cancer research stories worth following include a study on post-traumatic stress disorder after a cancer diagnosis.
Two FDA approvals for immunotherapy treatments highlight cancer research news this summer. But the extremely high costs of new cancer therapies are yet to be addressed.
New clinical trials will test whether the addition of progesterone could improve treatment for hormone receptor-positive breast cancer.